CLINICAL_TRIALS
trial_result
· 2024-09-24
Clinical Trial Update: A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS) [Phase 1, Phase 2]
Summary
A Phase 1/2 biomarker study evaluating MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis has completed enrollment and posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: MediciNova | Conditions: Amyotrophic Lateral Sclerosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-09-24